09:14:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandStorbritannien
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AstraZeneca är ett globalt bioläkemedelsbolag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom terapiområdena som berör andningsvägar, hjärta/kärl/metabolism och cancer. Utöver huvudverksamheten är bolaget även aktiva inom autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamma inom samtliga globala regioner och har sitt huvudkontor i Cambridge, Storbritannien.

Kalender

2021-11-12 Kvartalsrapport 2021-Q3
2021-08-12 Halvårsutdelning AZN 7.72
2021-07-29 Kvartalsrapport 2021-Q2
2021-04-30 Kvartalsrapport 2021-Q1
2021-02-25 Halvårsutdelning AZN 15.76
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-13 Halvårsutdelning AZN 7.87
2020-07-30 Kvartalsrapport 2020-Q2
2020-04-29 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 Halvårsutdelning AZN 18.32
2020-02-14 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-08 Halvårsutdelning AZN 8.49
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-26 Kvartalsrapport 2019-Q1
2019-04-26 Årsstämma 2019
2019-02-28 Halvårsutdelning AZN 17.46
2019-02-14 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-09 Halvårsutdelning AZN 7.92
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-18 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Halvårsutdelning AZN 14.97
2018-02-02 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-08-10 Halvårsutdelning AZN 7.4
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 Kvartalsrapport 2017-Q1
2017-04-27 Årsstämma 2017
2017-02-16 Halvårsutdelning AZN 16.57
2017-02-02 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-11 Halvårsutdelning AZN 7.81
2016-07-28 Kvartalsrapport 2016-Q2
2016-04-29 Årsstämma 2016
2016-04-29 Kvartalsrapport 2016-Q1
2016-02-18 Halvårsutdelning AZN 16.26
2016-02-04 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-13 Halvårsutdelning AZN 7.71
2015-07-30 Kvartalsrapport 2015-Q2
2015-04-24 Årsstämma 2015
2015-04-24 Kvartalsrapport 2015-Q1
2015-02-19 Halvårsutdelning AZN 15.62
2015-02-05 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-13 Halvårsutdelning AZN 6.2
2014-07-31 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-24 Årsstämma 2014
2014-02-19 Halvårsutdelning AZN 12.41
2014-02-06 Bokslutskommuniké 2013
2013-10-31 Kvartalsrapport 2013-Q3
2013-08-14 Halvårsutdelning AZN 5.92
2013-08-01 Kvartalsrapport 2013-Q2
2013-08-01 Analytiker möte 2013
2013-04-25 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-13 Halvårsutdelning AZN 12.08
2013-01-31 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-10-25 Analytiker möte 2012
2012-08-08 Halvårsutdelning AZN 6.26
2012-07-26 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-04-26 Årsstämma 2012
2012-02-15 Halvårsutdelning AZN 13.21
2012-02-02 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-03 Halvårsutdelning AZN 5.33
2011-07-28 Kvartalsrapport 2011-Q2
2011-04-28 Kvartalsrapport 2011-Q1
2011-04-28 Årsstämma 2011
2011-02-02 Halvårsutdelning AZN 11.99
2011-01-27 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-04 Halvårsutdelning AZN 5.12
2010-07-29 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-02-03 Halvårsutdelning AZN 12.43
2010-01-28 Bokslutskommuniké 2009
2009-10-29 Kvartalsrapport 2009-Q3
2009-08-05 Halvårsutdelning AZN 4.41
2009-07-30 Kvartalsrapport 2009-Q2
2009-04-30 Kvartalsrapport 2009-Q1
2009-04-30 Årsstämma 1
2009-02-04 Halvårsutdelning AZN 12.02
2008-08-06 Halvårsutdelning AZN 3.34
2008-02-06 Halvårsutdelning AZN 8.61
2007-08-08 Halvårsutdelning AZN 3.49
2007-02-07 Halvårsutdelning AZN 8.6
2006-08-09 Halvårsutdelning AZN 3.6
2006-02-08 Halvårsutdelning AZN 7.02
2005-08-10 Halvårsutdelning AZN 2.99
2005-02-09 Halvårsutdelning AZN 4.497
2004-08-11 Halvårsutdelning AZN 2.2
2004-02-18 Halvårsutdelning AZN 3.91
2003-08-20 Halvårsutdelning AZN 2.07
2003-02-19 Halvårsutdelning AZN 3.99
2002-08-21 Halvårsutdelning AZN 2.21
2002-02-20 Halvårsutdelning AZN 5.01
2001-08-22 Halvårsutdelning AZN 2.44
2001-02-21 Halvårsutdelning AZN 4.49
2000-09-04 Halvårsutdelning AZN 2.1
2000-03-08 Halvårsutdelning AZN 4.01
1999-09-06 Halvårsutdelning AZN 1.89
1999-04-01 Split AZN 1:0.5045
1997-05-26 Split AZN 1:2
1993-06-14 Split AZN 1:5
1987-06-04 Split AZN 1:2
2021-05-19 23:01:47

Lynparza is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer

Calquence shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukaemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib

Imfinzi five-year data represent longest-ever survival reported in a Phase III immunotherapy trial in unresectable Stage III lung cancer

AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, 4 to 8 June 2021.

More than 100 abstracts will feature 21 approved and potential new medicines across the Company's industry-leading oncology portfolio, with four abstracts selected as late-breakers, 12 oral presentations and one plenary presentation.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "Our data at ASCO this year show our unwavering resolve to revolutionise cancer care and strengthen our leading portfolio in lung and breast cancers as well as haematology. New results for Lynparza and Imfinzi continue to validate our strategy of treating cancer early in settings with curative intent, and data for Calquence deliver on our commitment to improve the patient experience by demonstrating efficacy with safe, tolerable medicines."

Cristian Massacesi, Senior Vice President, Head of late-stage development, Oncology R&D said: "Over the past few years, the outlook for breast cancer patients with BRCA mutations has radically changed, and the OlympiA data at ASCO will represent another critical step forward. We have an opportunity to fundamentally change the prognosis for women with high-risk early disease and usher in a potential new standard of care in the adjuvant setting. Additionally, promising data in triple-negative breast cancer will challenge current treatment expectations and bring hope for new approaches in this aggressive form of the disease."

Redefining survival by treating cancer earlier

A plenary presentation of results from the OlympiA Phase III trial in early breast cancer will highlight the impact of Lynparza (olaparib) on the risk of disease recurrence versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Lynparza is the first PARP inhibitor to demonstrate clinical benefit as an adjuvant treatment in early breast cancer. In February 2021 (https://www.astrazeneca.com/media-centre/press-releases/2021/olympia-trial-of-lynparza-idmc-recommend-early-analysis.html), the trial's Independent Data Monitoring Committee recommended moving to early primary analysis based on a planned interim analysis showing a sustainable and clinically relevant treatment effect in the primary endpoint of invasive disease-free survival.

Five-year overall survival data from the PACIFIC Phase III trial will continue to support the unprecedented and sustained survival benefits of Imfinzi (durvalumab) for patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who have not progressed following concurrent chemoradiation therapy. These data represent the longest-ever survival reported in a Phase III trial of immunotherapy in this treatment setting.

Additionally, an oral presentation of Phase II data from the externally sponsored GeparNuevo trial conducted by the German Breast Group will show initial potential of Imfinzi to improve outcomes in patients with early triple-negative breast cancer (TNBC) when added to standard neoadjuvant chemotherapy.

Transforming the patient experience

Four-year follow-up data from the ELEVATE-TN trial will confirm the sustained clinical benefit of either Calquence monotherapy or Calquence in combination with obinutuzumab, providing flexibility to tailor treatment for adults with treatment-naïve chronic lymphocytic leukaemia (CLL).

In addition, an oral presentation of detailed results from the ELEVATE-RR Phase III trial will demonstrate significantly lower atrial fibrillation, fewer cardiac events and fewer discontinuations with Calquence (acalabrutinib) versus ibrutinib in adults with previously treated CLL at high risk for progression. ELEVATE-RR is the first head-to-head Phase III trial of two Bruton's tyrosine kinase inhibitors in CLL, confirming the favourable benefit-risk profile of Calquence for patients with CLL.

Updated data from DESTINY-Gastric01 and DESTINY-CRC01 will further support the potential role of Enhertu (trastuzumab deruxtecan) across HER2-targetable cancers. Additionally, data from a subgroup analysis of previously treated HER2-positive breast cancer patients with brain metastases in the DESTINY-Breast01 trial will reinforce the commitment to understanding the potential benefit of Enhertu in hard-to-treat patient populations.

Initial results will be shared from the BEGONIA Phase Ib/II trial testing Imfinzi combinations in metastatic TNBC, including with Enhertu. Also, data will be shared from a Phase II trial with ceralasertib, an ataxia telangiectasia and rad3-related (ATR) kinase inhibitor, in combination with Imfinzi showing that this combination demonstrated promising anti-tumour activity in melanoma patients for whom prior anti-PD1 treatment had failed.

Additional evidence will underscore the need for improved central nervous system control and the role of next-generation tyrosine kinase inhibitors (TKIs) such as Tagrisso (osimertinib) in the treatment of advanced epidermal growth factor (EGFR)-mutated NSCLC, as shown in the REFLECT retrospective real-world analysis of first- and second-generation TKIs.

Advancing an industry-leading clinical development programme

In all, AstraZeneca will share 18 posters at ASCO describing trials-in-progress exploring novel medicines and combinations across multiple types and stages of cancer. These posters include:
  • Datopotamab deruxtecan (Dato-DXd) - the TROPION-Lung01 Phase III trial testing datopotamab deruxtecan in patients with previously treated metastatic NSCLC, and the BEGONIA trial testing Imfinzi in combination with datopotamab deruxtecan in metastatic TNBC
  • Enhertu - trials testing Enhertu alone or in various combinations, including: DESTINY-Breast07, DESTINY-PanTumor01, and DESTINY-CRC02
  • Imfinzi - the MATTERHORN Phase III trial of neoadjuvant-adjuvant Imfinzi and chemotherapy in resectable gastric and gastroesophageal junction cancer, and the BEGONIA Phase I/II trial testing Imfinzi in novel combinations for 1st-line treatment of patients with TNBC, including with Enhertu and datopotamab deruxtecan.
  • Calquence - the ESCALADE Phase III trial of Calquence in combination with standard chemotherapy for patients age 65 and younger newly diagnosed with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma
  • Camizestrant (AZD9833) - the SERENA-4 Phase III trial comparing camizestrant, a next-generation oral selective oestrogen receptor degrader (SERD), plus palbociclib, versus anastrozole plus palbociclib, in patients with oestrogen receptor-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease
  • Adavosertib - the ADAGIO Phase II multicentre trial of the WEE1 inhibitor adavosertib as a treatment for recurrent or persistent uterine serous carcinoma, a highly aggressive form of endometrial cancer

Collaboration in the scientific community is critical to improving outcomes for patients. Lynparza is developed and commercialised in collaboration with MSD (Merck & Co., Inc. in the US and Canada). AstraZeneca is collaborating with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to develop and commercialise Enhertu and datopotamab deruxtecan globally.

Key AstraZeneca presentations during the 2021 ASCO Annual Meeting[1]

[]
Lead author Abstract title Presentation details[2]
Immuno
-Oncology
Spigel, D Five-year Abstract #8511Poster Discussion SessionLung
survival outcomes Cancer-Non-Small Cell Local-Regional/Small
with durvalumab Cell/Other Thoracic Cancers 4 June 2021
after
chemoradiotherapy
in unresectable
stage III NSCLC:
An update from
the PACIFIC
trial.
Janjigian, MATTERHORN: Abstract #TPS4151Poster
Y Efficacy and SessionGastrointestinal
safety of Cancer-Gastroesophageal, Pancreatic, and
neoadjuvant Hepatobiliary 4 June 2021
-adjuvant
durvalumab and
FLOT chemotherapy
in resectable
gastric and
gastroesophageal
junction cancer-A
randomized,
double-blind,
placebo
-controlled,
phase 3 study.
McCoon, P T-cell receptor Abstract #4087Poster SessionGastrointestinal
pharmacodynamics Cancer-Gastroesophageal, Pancreatic, and
associated with Hepatobiliary 4 June 2021
survival and
response to
tremelimumab (T)
in combination
with durvalumab
(D) in patients
(pts) with
unresectable
hepatocellular
carcinoma (uHCC).
Schmid, P BEGONIA: Phase Abstract #1023Poster Discussion Session Breast
1b/2 study of Cancer-Metastatic 4 June 2021
durvalumab (D)
combinations in
locally
advanced/metastati
c triple-negative
breast cancer
(TNBC)-Initial
results from arm
1, d+paclitaxel
(P), and arm 6,
d+trastuzumab
deruxtecan (T
-DXd).
Schmid, P BEGONIA: Phase Abstract #TPS1105Poster SessionBreast
1b/2, open-label, Cancer-Metastatic4 June 2021
platform study of
the safety and
efficacy of
durvalumab (D) ±
paclitaxel (P)
with novel
oncology
therapies for
first line
metastatic triple
-negative breast
cancer (mTNBC):
Addition of Arm
7, D +
datopotamab
deruxtecan (Dato
-DXd; DS-1062).
Kwon, M Phase II study of Abstract #9514Poster Discussion
ceralasertib SessionMelanoma/Skin Cancers4 June 2021
(AZD6738), in
combination with
durvalumab in
patients with
metastatic
melanoma who have
failed prior anti
-PD-1 therapy.
Suárez, C Clinical activity Abstract #4511Poster Discussion Session
of durvalumab and Genitourinary Cancer-Kidney and Bladder 4 June
savolitinib in 2021
MET-driven,
metastatic
papillary renal
cancer.
Tumour
drivers and
resistance
Janzic, U Real-world Abstract #9086Poster SessionLung Cancer-Non
outcomes and -Small Cell Metastatic 4 June 2021
clinical
characteristics
of patients with
brain metastases
from EGFR mutated
non-small cell
lung cancer: Data
from a large
retrospective
study (REFLECT).
Im, S-A SERENA-4: A phase Abstract #TPS1101Poster SessionBreast
3 comparison of Cancer-Metastatic4 June 2021
AZD9833
(camizestrant)
plus palbociclib,
versus
anastrozole plus
palbociclib, for
patients with ER
-positive, HER2
-negative
advanced breast
cancer who have
not previously
received systemic
treatment for
advanced disease.
Tada, H Adjuvant Abstract #8501Oral Abstract SessionLung
gefitinib versus Cancer-Non-Small Cell Local-Regional/Small
cisplatin/vinorelb Cell/Other Thoracic Cancers6 June 2021
ine in Japanese
patients with
completely
resected, EGFR
-mutated, stage
II-III non-small
cell lung cancer
(IMPACT,
WJOG6410L): A
randomized phase
3 trial.
Antibody
drug
conjugates
Yoh, K A randomized, Abstract #TPS9127Poster SessionLung Cancer -
phase 3 study of Non-small Cell Metastatic4 June 2021
datopotamab
deruxtecan (Dato
-DXd; DS-1062)
versus docetaxel
in previously
treated advanced
or metastatic non
-small cell lung
cancer (NSCLC)
without
actionable
genomic
alterations
(TROPION-Lung01).
Andre, F Trastuzumab Abstract #TPS1096Poster SessionBreast
deruxtecan (T Cancer-Metastatic4 June 2021
-DXd)
combinations in
patients with
HER2-positive
advanced or
metastatic breast
cancer: A phase
1b/2, open-label,
multicenter, dose
-finding and dose
-expansion study
(DESTINY
-Breast07).
Li, BT A phase 2, Abstract #TPS3162Poster SessionDevelopmental
multicenter, open Therapeutics-Molecularly Targeted Agents and
-label study Tumor Biology4 June 2021
evaluating
trastuzumab
deruxtecan (T
-DXd) for the
treatment of
solid tumors
harboring
specific HER2
-activating
mutations
(DESTINY
-PanTumor01).
Yoshino, T Trastuzumab Abstract #3505Oral Abstract
deruxtecan (T SessionGastrointestinal Cancer-Colorectal and
-DXd; DS-8201) in Anal7 June 2021
patients (pts)
with HER2
-expressing
metastatic
colorectal cancer
(mCRC): Final
results from a
phase 2,
multicenter, open
-label study
(DESTINY-CRC01).
Raghav, K Trastuzumab Abstract #TPS3620Poster
deruxtecan in SessionGastrointestinal Cancer-Colorectal and
patients with Anal4 June 2021
HER2
-overexpressing
locally advanced,
unresectable, or
metastatic
colorectal cancer
(mCRC): A
randomized,
multicenter,
phase 2 study
(DESTINY-CRC02).
Jerusalem, Trastuzumab Abstract #526Poster SessionBreast Cancer-
G deruxtecan (T Local/Regional/Adjuvant4 June 2021
-DXd) in patients
with HER2+
metastatic breast
cancer with brain
metastases: a
subgroup analysis
of the DESTINY
-Breast01 trial.
Yamaguchi, Trastuzumab Abstract #4048Poster SessionGastrointestinal
K deruxtecan (T Cancer-Gastroesophageal, Pancreatic, and
-DXd; DS-8201) in Hepatobiliary4 June 2021
patients with
HER2-positive
advanced gastric
or
gastroesophageal
junction (GEJ)
adenocarcinoma:
Final overall
survival (OS)
results from a
randomized,
multicenter, open
-label, phase 2
study (DESTINY
-Gastric01).
DNA damage
response
Tutt, A OlympiA: A phase Abstract #LBA1Plenary Session6 June 2021,
3, multicenter, 1:00pm EDT
randomized,
placebo
-controlled trial
of adjuvant
olaparib after
(neo)adjuvant
chemotherapy in
patients with
germline BRCA1/2
mutations and
high risk HER2
-negative early
breast cancer.
Liu, JF ADAGIO: A phase Abstract #TPS5612Poster SessionGynecologic
IIb, open-label, Cancer4 June 2021
single-arm,
multicenter study
assessing the
efficacy and
safety of
adavosertib
(AZD1775) as
treatment for
recurrent or
persistent
uterine serous
carcinoma.
Poveda, A Olaparib Abstract #5545Poster SessionGynecologic
maintenance Cancer4 June 2021
monotherapy for
non-germline
BRCA1/2-mutated
(non-gBRCAm)
platinum
-sensitive
relapsed ovarian
cancer (PSR OC)
patients (pts):
Phase IIIb
OPINION primary
analysis.
Matthews, Olaparib Abstract #5515Poster Discussion Session
CA treatment (Tx) in Gynecologic Cancer4 June 2021
patients (pts)
with platinum
-sensitive
relapsed ovarian
cancer (PSR OC)
by BRCA mutation
(BRCAm) and
homologous
recombination
deficiency (HRD)
status: Overall
survival (OS)
results from the
phase II LIGHT
study.
Pautier, P Progression-free Abstract #5514Poster Discussion Session
survival (PFS) Gynecologic Cancer4 June 2021
and second PFS
(PFS2) by disease
stage in patients
(pts) with
homologous
recombination
deficiency (HRD)
-positive newly
diagnosed
advanced ovarian
cancer receiving
bevacizumab (bev)
with
olaparib/placebo
maintenance in
the phase III
PAOLA-1/ENGOT
-ov25 trial.
Haematology
Byrd, J First results of Abstract #7500Oral Abstract Session
a head-to-head Hematologic Malignancies 7 June 2021
trial of
acalabrutinib
versus ibrutinib
in previously
treated chronic
lymphocytic
leukemia.
Sharman, JP Acalabrutinib ± Abstract #7509Poster Discussion
obinutuzumab SessionHematologic Malignancies4 June 2021
versus
obinutuzumab +
chlorambucil in
treatment-naïve
chronic
lymphocytic
leukemia: Elevate
-TN four-year
follow up.
Sehn, L ESCALADE: A phase Abstract #TPS7572Poster SessionHematologic
3 study of Malignancies 4 June 2021
acalabrutinib in
combination with
rituximab,
cyclophosphamide,
doxorubicin,
vincristine, and
prednisone (R
-CHOP) for
patients ≤65y
with untreated
non-germinal
center B
-cell-like (non
-GCB) diffuse
large B-cell
lymphoma (DLBCL).

[1]74 company-sponsored or supported abstracts will be presented at ASCO 2021.

[2]Beginning Friday 4 June 2021 09:00 EDT oral presentations, poster discussions and poster sessions will be available on demand for 180 days including video and slide presentations and discussant commentary.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).